Gastrointestinal Support GI side effects are the most common reason patients discontinue GLP-1 therapy
Moreover, preclinical and early phase clinical trials have confirmed the therapeutic potential of entero-pancreatic hormone combinations in obesity and/or metabolic complications such as T2D [33]
Most people tolerate them incredibly well, and when side effects do pop up, they are usually pretty mild
The 2026 Regulatory Landscape: FDA Volatility and Global Enforcement The regulatory status of therapeutic peptides in early 2026 is characterized by extreme legal volatility, unprecedented political intervention, and widespread market confusion spanning across global regulatory bodies, including the US Food and Drug Administration (FDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and the World Anti-Doping Agency (WADA)
To claim, share what your primary goal is: Sign up to get your discount code with texts to activate your 20% off By proceeding, you agree to receive marketing texts